03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Rare diseases
Dr Caroline Sevin: no photograph is held, so the academic plate is shown instead.
Academic
Dr Caroline Sevin
Hôpital du Kremlin Bicêtre in France, NEXUS trial investigator
1
0
0
Sept 2026Oct 2026Nov 2026to date
1
press citation on 1 topic since 25 Sept 2026 · last quoted 25 Sept 2026
02 Quoted on · 1 of 29 topics
Dr Caroline Sevin: key facts
- Kind of voice
- Academic
- Role
- Hôpital du Kremlin Bicêtre in France, NEXUS trial investigator
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 25 Sept 2026
04 On the record · press
What Dr Caroline Sevin has said
By outlet · linked articles
- pharmaphorum.com1
Where Dr Caroline Sevin has been quoted
- 01EU clears first drug therapy for rare disease cALDpharmaphorum.com · 25 Sept 2026
Verbatim
“With childhood cALD, neurodegeneration is irreversible, so it is critical to halt disease progression early, ideally, before symptoms surface and signs of neuroinflammation appear. That we now have a pharmacological treatment for early intervention is a major advance in our treatment of cALD.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Coventry tot's heartbreaking health battle after 'extremely rare' diagnosiscoventrytelegraph.net
- Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdlereuters.com
- 'Immoral lottery' - Mum's plea after losing daughter to rare diseasethewestmorlandgazette.co.uk
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.